Alectinib cleared in Japan

|By:, SA News Editor

The Japanese Ministry of Health, Labor and Welfare approves Roche's (RHHBY) alectinib for the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). The product will be available for sale later this year.

In June 2013, the FDA granted alectinib BTD status for ALK+ NSCLC patients who progress on crizotinib.